ADENURIC

Found in: Austria Australia Cyprus Spain France Lithuania Netherlands United Kingdom

Active ingredients

Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO.

Medicine classification

M04AA03

Febuxostat

M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production

Product monographs

ADENURIC Film-coated tablet

MPI, EU: SmPC

Identifiers

Pharmaceutical Benefits Scheme (AU)

Identifier(s): 10445R

Z-Index G-Standaard PRK (NL)

Identifier(s): 101788, 101796

Base de données publique des médicaments (FR)

Identifier(s): 61871331, 64493890

Centro de información online de medicamentos de la AEMPS (ES)

Identifier(s): 08447001, 08447003

Medicines & Healthcare Products Regulatory Agency (GB)

Identifier(s): 170310, 170312, 299543, 374287, 376203, 381148, 381150

Valstybinė vaistų kontrolės tarnyba (LT)

Identifier(s): 1032555, 1032556, 1032557, 1032558, 1063623, 1063624, 1063625, 1063626, 1063627, 1063628, 1063629, 1063630, 1079546, 1079547, 1079548, 1079549, 1079550, 1079551, 1079552, 1079553, 1079554, 1079555, 1079556, 1079557